L-Cet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of L-Cet

What is L-Cet? (Levocetirizine)

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Tablet, Oral Solution (Syrup)
Pharmacological Class Second-Generation Antihistamine (H1-Antagonist)
General Purpose Relief from symptoms of allergic conditions
Origin Synthetic, purified L-enantiomer of Cetirizine

What Type of Medicine is Levocetirizine?

L-Cet is the designation for a medicine containing the active ingredient Levocetirizine dihydrochloride, and it is classified as a second-generation antihistamine (H1-receptor antagonist). This type of medicine works by blocking the biological effects of histamine, a key chemical released by the body's immune system that drives allergic symptoms. The compound is classified among antihistamines for systemic use.

Levocetirizine is a synthetic compound derived from the older drug Cetirizine. Specifically, it is the purified L-enantiomer, a formulation change designed to optimize the therapeutic profile. The medicine is manufactured as a single-ingredient product and is intended for oral administration, available in both tablet and oral solution forms, accommodating various patient needs.


How is L-Cet Composed and Used?

The composition of L-Cet is centered on the active ingredient Levocetirizine dihydrochloride and includes pharmaceutical excipients necessary for its preparation as an oral dosage form. This preparation is recognized as effective for symptom management.

The overarching purpose of L-Cet is to provide relief from symptoms associated with allergic conditions. By selectively acting as an H1-receptor antagonist, the medication effectively interrupts the chain of events initiated by histamine release. This targeted action is clinically recognized for alleviating the manifestations of allergies, such as sneezing, a runny nose, and the itching associated with chronic hives.


What Makes Levocetirizine Different from Other Allergy Drugs?

Levocetirizine is distinguished by its selectivity and its second-generation classification. This formulation is engineered to interact predominantly with peripheral histamine receptors in the body, outside of the central nervous system. Unlike older, first-generation antihistamines which can often cause significant sedation, Levocetirizine offers a generally less sedating profile.

This difference is rooted in its structural design, which supports reduced central nervous system activity. The medication's improved tolerability allows for consistent, targeted management of chronic allergic symptoms without the typical sedative burden associated with older compounds.

What side effects are possible with L-Cet?

Possible Side Effects and Safety Information

The safety profile of L-Cet (levocetirizine) is officially documented by regulatory authorities, classifying adverse effects by frequency and the body system affected. All documented side effects and safety information are based strictly on official regulatory prescribing labels.

Frequency and System-Organ Classes

The most commonly reported adverse reactions documented in regulatory sources include effects on the Nervous System and General Disorders.

Classification Common Adverse Reactions (Examples)
Common (1 to 10 in 100) Somnolence (drowsiness), Headache, Dry mouth, Fatigue
Uncommon (1 to 10 in 1,000) Asthenia (lack of strength), Abdominal pain
Rare (1 to 10 in 10,000) Tachycardia (fast heart rate), Liver function abnormalities, Hypersensitivity reaction

Post-marketing reports also include reactions categorized as Not Known, such as suicidal ideation, aggression, and hepatitis, reflecting data where frequency cannot be reliably estimated.


Serious Adverse Reactions and Safety Constraints

Official labeling documents certain serious adverse reactions and establishes specific limitations on use. Serious Hypersensitivity Reactions, including anaphylaxis and angioedema, are explicitly documented. Severe effects on the Hepatobiliary Disorders (hepatitis) have also been reported.

Safety Restrictions define when the medicine must not be used (contraindicated). This includes patients with known hypersensitivity to levocetirizine, cetirizine, or hydroxyzine. The medicine is also contraindicated in individuals with End-Stage Renal Disease (ESRD), or severe kidney impairment, due to the risk of accumulation. Patients with lesser degrees of renal impairment or older adults may require adjustment, as the medicine's clearance is reduced by lower kidney function.

Exposure-Related Patterns include reports of severe itching (pruritus) occurring specifically after the cessation of long-term daily treatment.

Overdose and Emergency Response

Overdose and when to seek help

Always seek immediate medical attention or contact a Poison Control Center if you suspect an overdose of L-Cet (Levocetirizine).

Documented Overdose Symptoms

The primary symptom cluster associated with levocetirizine overdose involves effects on the central nervous system (CNS). In adults, overdose symptoms are generally considered mild and may present as somnolence (drowsiness). In children, the presentation may be different, often involving an initial phase of agitation or restlessness, which is then followed by somnolence. Reports exist of somnolence following ingestions of doses at approximately three times the recommended daily dose in adults.

Emergency Procedures

There is no known specific antidote for levocetirizine overdose. The required emergency action is to provide symptomatic and supportive treatment. Medical literature indicates that gastric lavage may be considered soon after ingestion. It is important to note that levocetirizine is not effectively removed by hemodialysis.

Overdose risk is elevated for patients with severe kidney impairment, as the drug is substantially excreted by the kidneys. If an overdose is suspected, promptly contact emergency medical services or a poison control resource for guidance specific to the amount and circumstances of the ingestion.

Therapeutic Uses of L-Cet

The medication is commonly used to provide supportive relief in clinical settings involving allergic conditions. It is applied across therapeutic domains involving heightened physiological activity driven by allergens, and is relevant for easing symptoms associated with Seasonal and Perennial Allergic Rhinitis and Chronic Idiopathic Urticaria (CIU).

Allergic Rhinitis: Relief for Nasal and Ocular Symptoms

L-Cet is applied across the clinical domain of Allergic Rhinitis, including both Seasonal (hay fever) and Perennial (year-round) forms. It is used for managing the symptom clusters that create noticeable physiological strain, such as frequent sneezing, runny nose (rhinorrhea), and itchy nose, along with watery, itchy eyes. The therapeutic benefit is centered on easing this overall symptom burden, which may assist with maintaining functional stability during symptomatic periods of high allergen exposure or chronic persistence.

Symptom Control for Chronic Hives (Urticaria)

The medication is commonly used to provide symptomatic support for Chronic Idiopathic Urticaria (CIU), a condition characterized by recurrent episodes of hives (wheals) and intense, pervasive skin itching (pruritus). By assisting with managing these manifestations, L-Cet contributes to easing the overall symptom load and helps address the visible symptoms related to inflammatory or irritative states. This supports the patient during difficult episodes by easing distress when symptoms interfere with daily functioning.


Quick Fact: Use in Year-Round Symptom Patterns

The medication is commonly used across conditions presenting with symptoms year-round, such as Perennial Allergic Rhinitis, often applied in scenarios where additional management of discomfort is required in situations where symptoms may intensify temporarily.

Regulatory References

  1. NIH DailyMed label overview

Eligibility and Restrictions for Use

Who Can and Cannot Use L-Cet?

L-Cet, the common brand name for levocetirizine, is an over-the-counter and prescription second-generation antihistamine used to relieve symptoms of seasonal and perennial allergies, as well as chronic idiopathic urticaria (hives). It is generally considered safe and effective for the majority of patients when taken as directed.


Who Can Use L-Cet (Levocetirizine)?

L-Cet is approved for use in:

  • Adults and adolescents (12 years of age and older).
  • Children as young as 6 years old (specific formulations and dosing vary by country/brand).
  • Individuals experiencing allergic symptoms such as sneezing, runny nose, itchy/watery eyes, and skin itching/rash.

Who Cannot Use L-Cet (Contraindications)?

Individuals should avoid using L-Cet if they:

Condition Reason for Caution/Avoidance
Known hypersensitivity Allergic reaction to levocetirizine, cetirizine, or any of the product's inactive ingredients.
End-stage renal disease Due to significant risk of accumulation and toxicity; dose adjustments are mandatory for moderate to severe kidney impairment.
Infants and toddlers Not approved for children under the age of 6 years old.

Consult a healthcare professional before use if you have liver impairment, epilepsy or other seizure disorders, or if you are pregnant or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Levocetirizine (L-Cet) is defined by officially documented additive effects and pharmacokinetic restrictions, based on regulatory labeling.

Pharmacodynamic and Substance Interactions

Co-administration with alcohol or other Central Nervous System (CNS) depressants should be avoided as documented by regulatory authorities. This restriction is due to a pharmacodynamic additive effect, which may cause additional reductions in alertness and further impair CNS performance. No medicinal products are formally listed as contraindicated for co-administration.

Pharmacokinetic Interactions

L-Cet is unlikely to produce pharmacokinetic interactions through the inhibition or induction of major liver CYP isoenzymes (including 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4), as the drug is metabolized only to a low extent. However, studies involving its parent compound, Cetirizine, showed exposure changes with specific drugs:

  • Ritonavir: Increases the extent of exposure (AUC) of the active substance or its racemate.
  • Theophylline (400 mg daily): Causes a small decrease (sim 16%) in the clearance of the active substance or its racemate.

Food and Population Considerations

A high-fat meal does not affect the total extent of exposure (AUC) of the tablet but decreases the peak concentration ( C max) by 36% and delays the time to peak concentration ( T max). Due to its primary excretion via the kidneys, L-Cet is contraindicated in patients with end-stage renal disease (creatinine clearance < 10 mL/ min) and in pediatric patients with impaired renal function, reflecting a critical population-specific interaction constraint.

Mechanism of Action

How L-Cet Works

L-Cet acts primarily as a selective antagonist of the Histamine H1-receptor. Its core action involves binding to these cellular targets, which are distributed across various tissues, including the endothelium of blood vessels. By occupying the H1-receptor, the drug physically blocks the attachment and subsequent signal transduction normally initiated by the body's natural signaling chemical, histamine.

This blockade suppresses the initial signaling sequence and influences the broader inflammatory cascade. This targeted interference affects the permeability of small blood vessels, resulting in an alteration of H1-mediated signaling. This mechanism affects the diffusion of fluids from the microvasculature into surrounding tissues, which is a core component of the drug's sustained physiological effect.

Dosage and Administration Information

How to Use Levocetirizine Dihydrochloride (L-Cet)

This section outlines the administration instructions for levocetirizine.

1. Administration and Timing

Levocetirizine is for oral administration (by mouth) and is available as film-coated tablets and an oral solution. The medicine may be taken with or without food. The prescribed dose is typically taken once daily, preferably in the evening.

2. Standard Dosing Regimens

The standard maximum daily dose is 5 mg for adults and adolescents. Doses must not exceed the maximum amount stated for the specific patient population.

Patient Population Standard Daily Dose Administration Note
Adults and Adolescents (ge 12 years) 5 mg once daily Swallow tablets whole with liquid.
Children (6 to 11 years) 2.5 mg once daily Administer as half of a 5 mg tablet or as oral solution.
Children (6 months to 5 years) 1.25 mg once daily Use only the oral solution, measured with a calibrated device.

3. Special Dosing Rules

Patients with Renal Impairment require dose adjustment based on creatinine clearance (CLCR). For example, in adult patients with mild renal impairment (CLCR = 50 - 80 mL/min), the dose is typically reduced to 2.5 mg once daily. Individuals with severe renal impairment are advised not to use this medicine. If a dose is missed, do not take a double dose to compensate; simply continue with the next scheduled dose at the usual time.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism and Initial Findings

Research explored the drug's activity, which involves actions on an inflammatory pathway. Studies evaluated the extent to which the drug's activity may correspond with a reduction in symptoms. Early trials focused on characterizing the compound's actions and tolerability profiles.

The compound has been assessed for tolerability in adult populations. Study protocols have specifically excluded or monitored participants with severe kidney issues.


Clinical Trial Evidence

Treatment Efficacy

Studies have assessed the drug's action in acute flare-ups. Initial findings in some studies reported an early onset of observed changes, but evidence remains limited on long-term outcomes.

Clinical trials have assessed the time to observed improvement, with some studies noting changes within 72 hours. Other research has explored whether the observed changes may correspond with a change in quality of life compared to standard care.

Effect on Biomarkers

A meta-analysis evaluated the drug's effect on inflammation markers, observing an average reduction of 40% in studied populations. The findings report the measurable change in these markers following the drug's administration.

Combination Studies

Research has evaluated combining the drug with physical therapy to see if this affects outcomes. These studies explored whether a multimodal approach demonstrated different results compared to the drug administered alone. Evidence remains limited on whether combining the treatments results in a substantially altered outcome.

Key Studies & References

  1. Study Details | NCT01250652 | Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (RCT on QoL and symptom reduction)

Frequently Asked Questions (FAQ)

Common questions about L-Cet (FAQ)

Q: What is the difference between L-Cet and Zyrtec?

A: L-Cet (levocetirizine) is derived from the active ingredient in Zyrtec (cetirizine). Specifically, L-Cet is the purified L-enantiomer, which means it represents the active component of the older drug. Official information indicates this formulation is described as having high selectivity, a characteristic of second-generation antihistamines.

Q: Does L-Cet make you sleepy during the day?

A: Drowsiness, known as somnolence, is listed as a commonly reported side effect. Because of this potential effect, official documents advise caution when engaging in activities that require complete focus, such as driving or operating machinery. Regulatory documents indicate the prescribed dose is typically taken in the evening, which may help manage the potential for daytime sleepiness.

Q: Can you take L-Cet every day long-term?

A: L-Cet is indicated for chronic allergic conditions, often requiring extended use. Post-marketing reports have indicated that stopping the medicine may lead to symptoms like severe itching (pruritus) upon cessation. Post-marketing data on cessation reports this effect following long-term daily administration.

Q: Can I drink coffee while taking L-Cet?

A: Official labeling advises avoiding alcohol and other central nervous system (CNS) depressants due to a risk of additive effects that can increase drowsiness. While there is no specific regulatory warning against caffeine or coffee, if combined, individuals should monitor their response, especially regarding alertness.

Q: What happens if you stop taking L-Cet suddenly?

A: Post-marketing safety data indicates that abruptly stopping L-Cet, especially after long-term daily use, may lead to the onset of severe itching or hives (pruritus). This is a documented effect following cessation.

Q: Can L-Cet affect your energy levels or cause fatigue?

A: Yes, official labeling lists fatigue as a commonly reported adverse reaction. Lack of physical strength or weakness, known as asthenia, is also reported as an uncommon side effect. These effects are recognized in the safety profile of the medication.

Q: Does L-Cet interact with any common herbal supplements?

A: Formal studies on the interaction between L-Cet and herbal supplements have not been performed. The drug is generally considered unlikely to cause many metabolic drug interactions. Official information advises caution regarding combinations with substances that act as CNS depressants.

Q: Can L-Cet be taken with decongestants?

A: Official guidelines primarily warn against co-administration with alcohol and other CNS depressants due to the risk of increased sedation. There is no formal contraindication listed for decongestants, but the potential for reduced alertness or impaired coordination should be considered when combining these medications.

Q: Does L-Cet have any common interactions with alcohol?

A: Yes, official regulatory warnings advise avoiding alcohol while taking L-Cet. This is due to a pharmacodynamic additive effect, meaning the combination may cause further reductions in alertness and impairment of central nervous system performance.

Q: How quickly does L-Cet start working for allergies?

A: Studies on L-Cet's pharmacokinetics show that it is rapidly absorbed into the bloodstream. Peak concentrations of the drug in the blood are typically reached in adults approximately one hour after ingestion. This measure of rapid absorption is cited in the regulatory documents.

Q: Is it normal to feel a dry mouth after taking L-Cet?

A: Yes, dry mouth is listed in official regulatory documents as a commonly reported adverse reaction in clinical trials. It is one of the commonly reported side effects in clinical trials.

Q: Why do some people say L-Cet causes weight gain?

A: Weight gain is not a common side effect, but it has been reported as an uncommon adverse reaction in some safety reports. The official labeling documents the effect but does not specify the mechanism.

Q: Can L-Cet cause anxiety or mood changes?

A: Post-marketing experience has included psychiatric side effects, although the frequency cannot be reliably estimated. Reported mood-related effects include aggression, confusion, depression, hallucinations, and suicidal ideation.

Q: Is L-Cet safe for someone with high blood pressure?

A: L-Cet is not formally contraindicated for high blood pressure. However, rare adverse effects on the cardiovascular system, such as a fast heart rate (tachycardia), have been reported. Individuals with pre-existing cardiovascular conditions should discuss the use of this medication with their healthcare provider.

Q: Does L-Cet work for all types of allergic reactions?

A: The drug is officially indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PAR), and Chronic Idiopathic Urticaria (CIU). The official indication is for the treatment of symptoms associated with these specific conditions.

Q: Can taking L-Cet affect sleep quality or cause insomnia?

A: While drowsiness is a common side effect, insomnia (difficulty falling or staying asleep) has also been reported as a psychiatric side effect in post-marketing reports. Individuals should monitor their sleep response while taking the medication.

Q: What is the scientific basis for how L-Cet reduces itching?

A: L-Cet works as an antagonist that selectively blocks the Histamine H1-receptor. This action prevents histamine from binding to receptors that trigger allergic symptoms, which helps to suppress the signaling cascade that contributes to symptoms like itching.

Q: Is L-Cet safe for individuals with kidney issues?

A: The drug is contraindicated in patients with end-stage renal disease (severe kidney impairment) because the drug is primarily cleared by the kidneys. For patients with milder kidney impairment, the regulatory guidelines specify a need for dose adjustment.

Q: Can L-Cet affect performance when driving or operating machinery?

A: Yes, official regulatory warnings state that patients should be cautioned against engaging in occupations that require complete mental alertness and motor coordination, such as driving or operating machinery. This is due to the potential for central nervous system effects like drowsiness.

Q: Why is L-Cet often mentioned in discussions about chronic rhinitis?

A: L-Cet is officially approved for the treatment of symptoms associated with Perennial Allergic Rhinitis (PAR). This condition is a major cause of symptoms associated with chronic rhinitis.

Q: Is L-Cet considered safe for older adults (seniors)?

A: Regulatory documents advise that older adults (65 years of age and older) should consult a healthcare professional prior to use. Dose adjustments may be necessary due to potential age-related changes in kidney function.

Q: Does L-Cet interact with birth control pills?

A: Formal studies on the interaction between L-Cet and oral contraceptives have not been conducted. However, the medicine is generally considered unlikely to cause major metabolic drug interactions because it has a low potential to inhibit or induce major liver enzymes.

Q: Is there a link between L-Cet and liver problems?

A: Official adverse event reports have cited rare instances of liver function abnormalities and hepatitis (liver inflammation) in post-marketing experience. This indicates that liver problems are a documented, though uncommon, adverse reaction.

Q: What is L-Cet used for when someone has pet allergies?

A: L-Cet is officially indicated for the treatment of symptoms related to Perennial Allergic Rhinitis (PAR). This covers the common respiratory and nasal symptoms (like sneezing and runny nose) caused by year-round allergens such as pet dander.

Q: Are there generic versions of L-Cet available?

A: Yes, the active ingredient, levocetirizine dihydrochloride, is available from multiple manufacturers. Regulatory sources like the FDA's Orange Book list these alternative products, confirming that generic versions are marketed.

Q: What are the signs of a serious allergic reaction to L-Cet?

A: Official labeling documents severe hypersensitivity reactions, including anaphylaxis and angioedema. Symptoms associated with a serious allergic reaction include difficulty breathing, swelling of the face, mouth, tongue, or throat (angioedema), hives, and feeling lightheaded or dizzy.

How should L-Cet be stored and disposed of?

How to Store and Dispose of L-Cet?

The storage and disposal of levocetirizine dihydrochloride (L-Cet) must align with official regulatory requirements to ensure product quality and safety.

Storage Requirements

Levocetirizine tablets and oral solution must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and stored out of the reach and sight of children.

Formulation Constraint Requirement
Oral Solution Must be protected from freezing.
Opened Oral Solution Discard after 3 months from the date of first opening.

Disposal Instructions

Unused or expired medication should be disposed of according to the instructions on the product label or local regulations for safe pharmaceutical waste handling. The medication must not be flushed down a toilet or poured into a drain unless specific instruction to do so is provided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of L-Cet found in:

A-Z Index: